The bovine milk formula lawsuit is a massive wave of litigation targeting Abbott Laboratories and Mead Johnson/Reckitt Benckiser, alleging that their cow’s milk-based infant formulas caused necrotizing enterocolitis — a devastating intestinal disease — in premature babies. With 779 cases now pending in federal multidistrict litigation and jury verdicts already exceeding $585 million combined, this has become one of the most significant product liability battles in recent years. In July 2024, a Missouri jury returned a staggering $495 million verdict against Abbott after finding that its Similac formula caused NEC in a baby girl born at 26 weeks who lost 75 percent of her intestines.
These lawsuits center on hospital-grade formulas and fortifiers — not the ordinary consumer formula sold on store shelves — that were fed to the most vulnerable patients in neonatal intensive care units. The families bringing these cases argue that both Abbott and Mead Johnson knew for years that cow’s milk-based products substantially increased the risk of NEC in premature infants but failed to warn parents or healthcare providers. No comprehensive federal settlement has been reached yet, though a second wave of bellwether trials is set to begin in August 2026. This article covers the current state of the litigation, the major verdicts that have reshaped the landscape, who qualifies to file a claim, and what estimated settlement payouts could look like.
Table of Contents
- What Is the Bovine Milk Formula Lawsuit and Who Is Being Sued?
- Major Jury Verdicts That Have Changed the Litigation Landscape
- The Federal MDL and Upcoming Bellwether Trials
- Who Qualifies to File a Bovine Milk Formula Lawsuit?
- Why Manufacturers Are Accused of Knowing the Risk
- Hospital Liability and the Role of Healthcare Providers
- What Comes Next for the NEC Formula Litigation
- Conclusion
- Frequently Asked Questions
What Is the Bovine Milk Formula Lawsuit and Who Is Being Sued?
The bovine milk formula lawsuit — formally known as the NEC baby formula litigation — targets two of the largest infant formula manufacturers in the world. Abbott Laboratories produces Similac Special Care and Similac Human Milk Fortifier, while Mead Johnson, now a subsidiary of Reckitt Benckiser, manufactures enfamil premature formulas. Both companies supply hospitals with specialized formulas designed for premature and low-birth-weight infants in neonatal intensive care units. The core allegation is straightforward: these companies knew that cow’s milk-based formulas carried a significantly higher risk of causing NEC compared to human breast milk, and they chose profits over disclosure. Necrotizing enterocolitis is not a minor complication. It is a condition in which intestinal tissue becomes inflamed and begins to die, sometimes requiring emergency surgery to remove portions of the bowel.
NEC carries a fatality rate of approximately 15 to 40 percent and predominantly strikes premature infants whose digestive systems are not yet developed enough to process bovine proteins. For the babies who survive, the consequences can be lifelong — short bowel syndrome, feeding difficulties, developmental delays, and in some cases, permanent brain damage from oxygen deprivation during medical crises. The federal cases have been consolidated into a multidistrict litigation in the U.S. District Court for the Northern District of Illinois under Master Docket 1:22-cv-00071, overseen by Judge Rebecca R. Pallmeyer. As of early 2026, 779 cases are pending in this MDL. The consolidation allows common pretrial issues — like whether the science supports a causal link between bovine formula and NEC — to be resolved efficiently before individual cases proceed to trial or settlement.
Major Jury Verdicts That Have Changed the Litigation Landscape
Three major verdicts have sent a clear signal to the manufacturers that juries are receptive to these claims, and each one has raised the stakes considerably. The first came in March 2024, when an Illinois state court jury in St. Clair County awarded $60 million against Mead Johnson for the death of premature baby Chance Dean, who developed NEC after being fed Enfamil. The jury deliberated for just two hours and returned a verdict $25 million higher than what the plaintiff’s own attorneys had requested — a rare outcome that speaks to how compelling the evidence was. The largest verdict to date came four months later. In July 2024, a St. Louis, Missouri jury found abbott liable for NEC injuries sustained by Robynn Davis, who was born at 26 weeks in August 2021. She developed NEC within 72 hours of being started on Similac, ultimately requiring the removal of 75 percent of her intestines.
She suffers from brain damage and will require lifetime care. The jury awarded $95 million in compensatory damages and an additional $400 million in punitive damages, for a total of $495 million. The verdict was supported by 9 of 12 jurors. However, not every case has gone the plaintiffs’ way, and families considering litigation should understand that outcomes vary. In December 2025, a Connecticut state court ordered Yale New Haven Hospital — not a manufacturer — to pay approximately $32 million after the hospital fed cow-based formula and fortifier to premature baby Aries-Reign Peterson without parental consent. The parents had specifically requested breast milk only. That case illustrates a different theory of liability — medical malpractice against a healthcare provider rather than product liability against a manufacturer. And on March 4, 2026, a Boston jury returned a defense verdict in a medical malpractice NEC case, showing that these claims are not guaranteed wins and the specific facts of each case matter enormously.
The Federal MDL and Upcoming Bellwether Trials
The federal multidistrict litigation has been building toward trial for several years, and a critical milestone occurred in May 2025 when Judge Pallmeyer denied defense Daubert motions seeking to exclude the plaintiffs’ general causation experts. This ruling preserved the core scientific theory underpinning the entire litigation — that cow’s milk-based formulas substantially increase NEC risk in premature infants. Had the judge excluded those experts, the litigation would have been effectively gutted. The denial of these motions was a significant win for plaintiffs and likely influenced the trajectory of settlement discussions. At a February 13, 2026 status conference, Judge Pallmeyer directed the parties to submit a revised case management order by April 16, 2026. The next major events on the calendar are the second-wave federal bellwether trials, all of which are against Abbott and its similac product line.
The first trial is scheduled for August 3, 2026, followed by a second on November 2, 2026, and a third on February 1, 2027. These cases involve Similac Special Care, Similac Human Milk Fortifier, and other Similac products given to premature infants. The outcomes of these bellwether trials will heavily influence any global settlement negotiations. For families with pending claims, the bellwether trial schedule is both encouraging and a test of patience. Bellwether trials serve as test cases that allow both sides to gauge how juries respond to the evidence, and strong plaintiff verdicts typically accelerate settlement talks. Given that state court juries have already returned verdicts totaling over $585 million, the manufacturers face considerable pressure heading into the federal trials.
Who Qualifies to File a Bovine Milk Formula Lawsuit?
Not every family whose infant experienced digestive problems after formula feeding has a viable claim. The litigation focuses specifically on premature and low-birth-weight infants who were fed cow’s milk-based formulas or fortifiers — typically in a hospital NICU setting — and subsequently developed necrotizing enterocolitis. The products at issue are hospital-grade formulas like Similac Special Care, Similac Human Milk Fortifier, and Enfamil Premature formulas. These are not the same products sold in grocery stores for healthy, full-term infants. The critical distinction matters for families evaluating whether they have a case.
A full-term baby who was fed standard Similac or Enfamil at home and experienced digestive discomfort is in a fundamentally different situation than a 26-week preemie who was given Similac Special Care in the NICU and developed NEC within days. Attorneys handling these cases typically look for medical records documenting prematurity, the specific formula administered in the hospital, a confirmed NEC diagnosis, and the resulting injuries or death. The tradeoff families face is between pursuing an individual lawsuit — which allows for potentially larger verdicts like the $495 million Missouri outcome — and participating in a broader settlement, which provides more certainty but likely lower payouts. Attorneys working in this space estimate that individual NEC lawsuit payouts may range from $50,000 to over $500,000 per case depending on the severity of injuries. Cases involving infant death or catastrophic lifelong injuries like short bowel syndrome and brain damage would be expected to fall at the higher end of that range, while cases involving NEC that resolved with less invasive treatment would be at the lower end.
Why Manufacturers Are Accused of Knowing the Risk
The negligence and failure-to-warn allegations are not based on hindsight. Plaintiffs’ attorneys have pointed to decades of medical literature establishing that breast milk is significantly safer than cow’s milk-based formula for premature infants, particularly when it comes to NEC risk. Studies dating back to the 1990s and earlier showed elevated NEC rates among formula-fed preemies compared to those receiving human milk. The manufacturers’ own internal documents and the medical community’s growing understanding of NEC risk factors form the backbone of these claims. One limitation families should be aware of is that proving an individual case requires more than just showing a general link between formula and NEC.
Defense attorneys have argued that NEC has multiple potential causes — prematurity itself, bacterial infection, reduced blood flow to the intestines, and other factors unrelated to feeding. In the Boston case that resulted in a defense verdict on March 4, 2026, the jury apparently was not persuaded that formula was the cause in that particular infant’s NEC. This underscores the importance of strong medical records and expert testimony tying the specific formula exposure to the specific NEC diagnosis in each case. The defense has also pursued a strategy of challenging the admissibility of plaintiffs’ scientific experts, though this approach failed at the federal level when Judge Pallmeyer denied the Daubert motions in May 2025. That ruling does not bind state courts, but it carries persuasive weight and signals that the scientific evidence supporting causation is robust enough to reach a jury.
Hospital Liability and the Role of Healthcare Providers
The December 2025 Connecticut verdict against Yale New Haven Hospital added another dimension to this litigation. In that case, Aries-Reign Peterson was born at 27 weeks in January 2018, and her parents had requested that she receive breast milk only. The hospital instead fed the infant cow-based formula and fortifier without parental consent, and the baby developed NEC.
The jury awarded $1.9 million for medical expenses and lost earnings plus $30 million for pain, suffering, and death. This case illustrates that liability may extend beyond the formula manufacturers to the hospitals and medical providers who administered the products, particularly when informed consent was not obtained. Families whose premature infants developed NEC should consider whether the hospital followed their feeding preferences and whether they were adequately warned about the risks of cow’s milk-based formula before it was given to their child.
What Comes Next for the NEC Formula Litigation
The next 12 months will likely be decisive for this litigation. With three federal bellwether trials scheduled between August 2026 and February 2027, Abbott in particular faces a gauntlet of jury trials that could add hundreds of millions of dollars to its exposure. The state court verdicts have already demonstrated that juries are willing to impose punitive damages — the $400 million punitive component of the Missouri verdict was a warning shot that future juries may follow. As reported by Law.com on March 11, 2026, Abbott faces yet another trial over preterm infant formula, keeping the pressure on the company from multiple fronts simultaneously.
Whether these trial pressures lead to a comprehensive federal settlement remains to be seen. The revised case management order due April 16, 2026 may provide more clarity on the timeline. For families who have not yet filed, the litigation remains open, and attorneys continue to evaluate new cases. Given the trajectory of the verdicts and the court’s favorable rulings on scientific evidence, the bovine milk formula lawsuit shows no signs of slowing down.
Conclusion
The bovine milk formula lawsuit represents one of the most consequential product liability litigations currently unfolding in the American legal system. More than $585 million in jury verdicts have been returned against Abbott and Mead Johnson, 779 federal cases remain pending before Judge Pallmeyer in Illinois, and three bellwether trials are set to begin in August 2026. The science connecting cow’s milk-based formula to NEC in premature infants has withstood judicial scrutiny, and the human cost behind each case — babies who lost their intestines, their health, or their lives — continues to drive this litigation forward.
Families of premature infants who were fed Similac Special Care, Similac Human Milk Fortifier, Enfamil Premature formulas, or similar cow’s milk-based hospital products and subsequently developed NEC should consult with an attorney experienced in this litigation. The estimated settlement range of $50,000 to over $500,000 per case depends heavily on individual circumstances, and the window to file remains open as the federal MDL continues to develop. With major trials on the horizon, 2026 and 2027 will shape whether this litigation resolves through a global settlement or continues case by case through the courts.
Frequently Asked Questions
What is necrotizing enterocolitis (NEC)?
NEC is a serious intestinal disease in which bowel tissue becomes inflamed and begins to die. It predominantly affects premature and low-birth-weight infants and carries a fatality rate of approximately 15 to 40 percent. Surviving infants may require surgical removal of portions of their intestines and can face lifelong complications including short bowel syndrome and developmental delays.
Which formula products are involved in the bovine milk formula lawsuit?
The lawsuits target hospital-grade cow’s milk-based formulas and fortifiers for premature infants, including Similac Special Care, Similac Human Milk Fortifier, and Enfamil Premature formulas. These are specialized products used in NICUs — not the standard consumer formulas sold in retail stores for healthy full-term infants.
Has there been a settlement in the NEC formula lawsuit?
No comprehensive federal settlement has been reached as of March 2026. However, state court jury verdicts totaling over $585 million have been returned against Abbott and Mead Johnson, and three federal bellwether trials are scheduled to begin in August 2026. These trial outcomes will likely influence future settlement negotiations.
How much could NEC formula lawsuit settlements be worth?
Attorneys estimate that individual NEC lawsuit payouts may range from $50,000 to over $500,000 per case, depending on the severity of injuries. Cases involving infant death or catastrophic injuries like the removal of significant portions of the intestines and brain damage would be expected to fall at the higher end of that range.
Can I still file a bovine milk formula lawsuit?
The litigation remains open and attorneys continue to evaluate new cases. Eligibility generally requires that a premature or low-birth-weight infant was fed cow’s milk-based formula or fortifier in a hospital setting and subsequently developed NEC. Medical records documenting the formula used and the NEC diagnosis are critical to building a viable claim.
Are hospitals also liable in NEC formula cases?
Potentially, yes. In December 2025, a Connecticut court ordered Yale New Haven Hospital to pay approximately $32 million after the hospital fed cow-based formula to a premature infant without parental consent, and the baby developed NEC and died. Hospital liability may apply when healthcare providers failed to obtain informed consent or did not warn parents about the risks of bovine-based formula for premature infants.